E-Learning Center
Join Our Network

Follow Imedex on Twitter

Register for an upcoming conference!

Phone: +1 (678) 242 0906

13th Annual Perspectives in Lung Cancer


13th Annual Perspectives in Thoracic Oncology

November 21 - 22, 2008

New York, New York, USA

New York Marriott East Side

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this educational activity for a maximum 12.5 of AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.


This educational activity is intended for oncologists, radiation therapists, thoracic surgeons, pulmonologists and other physicians in active clinical practice interested and/or involved in the management of patients with thoracic cancer.


After successful completion of this continuing medical education activity, participants should be able to:

• Describe the epidemiology of lung cancer and emerging screening techniques

• Discuss the methodology of smoking cessation

• Recommend the most appropriate management strategies for non-small cell lung cancer (NSCLC), including selecting patients fortherapy and predicting benefit

• Compare and contrast invasive versus non- invasive (MRI, CT, PET) procedures in the staging of lung cancer

• Recommend the most appropriate management strategies for small cell lung cancer

• Identify controversies in management of locally advanced NSCLC

• Analyze available and emerging treatment options in advanced NSCLC

• Translate the results of recent clinical trials in lung cancer and incorporate them into clinical practice

• Outline management strategies for esophageal cancer

• Outline management strategies for mesothelioma

• Describe the emerging role of targeted therapies in the treatment of thoracic malignancies and optimal strategies for patient selection

• Discuss surgical issues and controversies related to treatment of thoracic cancers


Jeffrey D. Bradley, MD
Siteman Cancer Center
St. Louis, Missouri

Barbara A. Burtness, MD
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Roger B. Cohen, MD
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Walter J. Curran, Jr., MD, FACR
Emory University
Atlanta, Georgia

Carolyn M. Dresler, MD, MPA
University of Arkansas for Medical Sciences
Little Rock, Arkansas

John R. Eckardt, MD
The Center for Cancer Care and Research
St. Louis, Missouri

Martin J. Edelman, MD
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland

David S. Ettinger, MD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Ramaswamy Govindan, MD
Washington University in St. Louis
School of Medicine
St. Louis, Missouri

Nasser H. Hanna, MD
Indiana University
Indianapolis, Indiana

Roy S. Herbst, MD, PhD
M. D. Anderson Cancer Center
Houston, Texas

Vera Hirsh, MD
McGill University
Montreal, Quebec, Canada

James R. Jett, MD
Mayo Clinic
Rochester, Minnesota

Mark G. Kris, MD
Memorial Sloan-Kettering Cancer Center
New York, New York

Rodney J. Landreneau, MD
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania

Corey J. Langer, MD, FACP
University of Pennsylvania
Philadelphia, Pennsylvania

John J. Nemunaitis, MD
Mary Crowley Medical Research Center
Dallas, Texas

Harvey I. Pass, MD
New York University
New York, New York

Roman Perez-Soler, MD
Albert Einstein Cancer Center
New York, New York

Helen J. Ross, MD
Mayo Clinic
Scottsdale, Arizona

Walter J. Scott, MD, FACS
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Gerard A. Silvestri, MD, MS
Medical University of South Carolina
Charleston, South Carolina

George R. Simon, MD
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida

Louis Souhami, MD
McGill University Faculty of Medicine
Montreal, Quebec, Canada

Eric Vallieres, MD, FRCSC
Swedish Cancer Institute
Seattle, Washington

Henry Wagner, MD
Pennsylvania State Cancer Institute
Hershey, Pennsylvania

Friday, November 21, 2008

Session I: Introductory lectures

8:10 am
Welcome Corey J. Langer, MD

8:20 am
Lung cancer – New millennial perspective on epidemiology, risk factors, and genetics
Mark G. Kris, MD

8:45 am
Saving lives pre-emptively: How to facilitate smoking cessation
Carolyn M. Dresler, MD, MPA

9:10 am
Lung cancer screening in 2008: Truth and consequences?
James R. Jett, MD

9:35 am
Panel discussion

9:55 am

Session II: Non-small cell lung cancer (NSCLC)

10:15 am
Case presentation Anatomic resection – Can we do more with less?
No – Rodney J. Landreneau, MD
Yes – Walter J. Scott, MD, FACS

11:00 am
Cost-effective staging in NSCLC
Gerard A. Silvestri, MD, MS

11:20 am
Is there a role for adjuvant radiotherapy in resected NSCLC?
Louis Souhami, MD

11:40 am
Panel discussion

12:00 pm

Session III: Locally advanced NSCLC

1:00 pm
Identifying the optimal approach for patients with locally advanced, unresectable NSCLC
Medical oncologist perspective - Corey J. Langer, MD
Radiation oncologist perspective - Walter J. Curran Jr., MD, FACR

1:45 pm
Management of locally advanced, potentially resectable NSCLC: Is surgery worth the morbidity?
Harvey I. Pass, MD

2:05 pm
Image-guided radiation therapy: Does dose escalation of RT in the face of standard chemotherapy enhance outcome?
Jeffrey D. Bradley, MD

2:25 pm
Targeting VEGF and EGFR in the treatment of locally advanced NSCLC
Ramaswamy Govindan, MD

2:45 pm
Panel discussion

3:05 pm

Session IV: Advanced NSCLC

3:25 pm
First-line treatment for advanced NSCLC: Has the time for molecular determination finally arrived?
Helen J. Ross, MD

3:45 pm
Optimizing patient selection with respect to targeted agents
Roman Perez-Soler, MD

4:05 pm
Second- and third-line treatment options in NSCLC: Is there a “state of the art?”
Nasser H. Hanna, MD

4:25 pm
Panel discussion

4:45 pm


Saturday, November 22, 2008

8:00 am
Welcome to day two
Corey J. Langer, MD

8:05 am
Special Topics in Thoracic Oncology -- Esophageal cancer: What’s new; What’s not?
Barbara A Burtness, MD

Session V: SCLC

8:25 am
Case presentation SCLC: Will we ever alter the standard paradigm in limited disease?
David S. Ettinger, MD

9:10 am
Prophylactic cranial irradiation (PCI): Why does this strategy make such a difference in SCLC?
Henry Wagner, MD

9:30 am
First- and second-line therapy in SCLC: Developing new agents in the face of therapeutic stagnation
John Eckardt, MD

9:50 am
Panel discussion

10:10 am

Session VI: Targeted therapies and immunomodulation

10:30 am
Bevacizumab: Has the clinical perspective been altered by AVAiL?
Vera Hirsh, MD

10:50 am
Beyond bevacizumab: Future role of angiogenesis inhibition and vascular disruption in NSCLC
Martin J. Edelman, MD

11:10 am
Beyond VEGF and angiogenesis inhibitors: New targets and agents that warrant attention in NSCLC
Roger B Cohen, MD

11:30 am
Will cetuximab eclipse the oral EGFR small molecule inhibitors? Does “FLEX” offer us more flexibility?
Roy S. Herbst, MD, PhD

11:50 am
Will vaccines have a role in early stage and locally advanced NSCLC?
John J. Nemunaitis, MD

12:10 pm
Panel discussion

12:30 pm

Session VII: Surgical controversies in thoracic oncology

1:35 pm
RFA vs wedge resection vs SBRT: How do we address the ever shrinking SPN (solitary pulmonary nodule)?
Walter J. Scott, MD, FACS

1:55 pm
Mediastinal lymph nodes: Does extent of dissection influence outcome?
Eric Vallieres, MD, FRCSC

2:15 pm
Special Topics in Thoracic Oncology -- Mesothelioma: Has survival plateaued after pemetrexed?
George R. Simon, MD

2:35 pm
Panel discussion

2:55 pm
Chairman summary and take home points
Corey J. Langer, MD

3:00 pm



Discounted . . . . . . . . . . . . . . . . . . . .$225.00
Payment received by September 18, 2008

Regular . . . . . . . . . . . . . . . . . . . .$325.00
Payment received by November 13, 2008

Full/Onsite . . . . . . . . . . . . . . . . . .$425.00
Payment received after November 13, 2008

Group discount (physicians only)* . . -$50.00
*Cannot be combined with any other discounts

Nurses/Residents/Students . . . . . . . $99.00
*Proof of eligibility must accompany registration

To Register: You may register online by November 13, 2008 at www.imedex.com, by calling Imedex at +1 (678) 242 0906 or by returning the registration form in this announcement by mail or fax. If you mail the form, please keep a copy for your records. Registration confirmations will be issued before the meeting.

Group Discounts: Each one of multiple registrants from the same institute or practice receive a $50 discount off the published registration fees, provided all registration forms and payments are received together. Only one discount will apply per physician.

Payment: To pre-register, registration and payment must be received no later than November 13, 2008. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Include the full name of the attendee and the name of the conference: Perspectives in Thoracic Oncology A040.01. An attendee is not registered until full payment is received.

Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the agenda.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than November 13, 2008. The amount of registration fees remitted, less a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after November 13, 2008.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

New York Marriott East Side
525 Lexington Avenue
New York, New York 10017
Tel: + 1 (212) 755 4000
Fax: +1 (212) 751 3440

When visiting the Big Apple, there`s no better place to stay than the New York Marriott East Side. Having just completed a $24 million guest room renovation, this hotel in Midtown Manhattan, NY is a treasure of rare distinction among other East Side New York hotels. The hotel`s 629 guestrooms and 17 suites feature luxurious bed linens, 32 inch plasma-screen HDTVs and ample business amenities. Guests will delight in the newly renovated health club and upgraded concierge lounge with outdoor terraces. Enjoy close proximity to Midtown Manhattan`s best attractions including Rockefeller Center, Broadway theaters and shopping on Madison Avenue.

For the convenience of attendees, a limited number of rooms have been reserved until October 31, 2008 at a discounted rate of $429 single/double occupancy, plus tax, currently at 13.375%. This rate is not guaranteed outside the conference dates or after October 31, 2008. Additional nights will be subject to rate and room availability.

To reserve your room please contact the New York Marriott East Side reservations department at +1 (212) 755 4000. Callers must identify themselves as being with the Perspectives in Thoracic Oncology group. Reservation requests received after October 31, 008 may not be guaranteed the group rate.



Corey J. Langer, MD, FACP
University of Pennsylvania
Philadelphia, Pennsylvania


Dear Colleague,
It is with great pleasure and enthusiasm that I invite you to attend the 13th Annual Perspectives in Thoracic Oncology. This fall’s conference, to be held November 21-22, 2008 at the New York Marriott East Side, promises to be our most exciting meeting yet! Over the past thirteen years, this meeting has become a premier source for updates in thoracic oncology; it provides attendees a forum to update their knowledge in the field, confirm their current practices and receive valuable take-home information on exciting new screening and staging modalities, management approaches and emerging treatment options. There is great need among thoracic oncology clinicians and researchers to obtain the latest information on the complex pathology and treatment of lung cancer. The field is constantly evolving and there are many issues in disease biology, management, and research that are intensely debated among those involved in these fields. This conference will be a great place to interact with your colleagues and learn from internationally renowned faculty, as well as the diverse mix of oncologists, surgeons, and pulmonologists. I hope you will be able to join me for this exciting two day meeting; I look forward to welcoming you to New York as the fall brings its beauty to this international city.

Corey J. Langer, MD, FACP


11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

The following companies have provided an unrestricted educational grant in support of this conference:


Genentech BioOncology &
OSI Oncology



EMD Serono







Several options are available to companies interested in supporting this conference. For more information, please contact Imedex at +1 (770) 751 7332, or by email at cme@imedex.com.